| scholarly article | Q13442814 |
| P50 | author | Erik Folch | Q51716590 |
| Daniel B Costa | Q55130362 | ||
| Suzanne E Dahlberg | Q57618814 | ||
| Paul A VanderLaan | Q59085821 | ||
| Scott Floyd | Q77462085 | ||
| Norihiro Yamaguchi | Q92003462 | ||
| Deepa Rangachari | Q98213310 | ||
| P2093 | author name string | Eric T Wong | |
| Mark S Huberman | |||
| Anand Mahadevan | |||
| Erik J Uhlmann | |||
| P2860 | cites work | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Q27851712 |
| Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. | Q27852316 | ||
| Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer? | Q31108157 | ||
| Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib | Q34393558 | ||
| EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer | Q34992513 | ||
| Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer | Q36016428 | ||
| The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations | Q36927984 | ||
| Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. | Q37238413 | ||
| Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer | Q37638241 | ||
| Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. | Q38206686 | ||
| Management and future directions in non-small cell lung cancer with known activating mutations | Q38214303 | ||
| Epidemiology of brain metastases | Q48829653 | ||
| EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases? | Q50688369 | ||
| CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. | Q54602410 | ||
| Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System | Q57407206 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 108-111 | |
| P577 | publication date | 2015-02-04 | |
| P1433 | published in | Lung Cancer | Q641464 |
| P1476 | title | Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers | |
| P478 | volume | 88 |
| Q90046288 | A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib - A drug intended for treatment of brain metastases in non-small cell lung cancer |
| Q55262467 | ALK inhibitors, resistance development, clinical trials. |
| Q37518624 | ALK: a tyrosine kinase target for cancer therapy |
| Q39121571 | AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases |
| Q34497467 | AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients |
| Q42698204 | Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study |
| Q27853360 | Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial |
| Q41820718 | Alectinib for the management of ALK-positive non-small cell lung cancer brain metastases |
| Q92424812 | Application of radiomics signature captured from pretreatment thoracic CT to predict brain metastases in stage III/IV ALK-positive non-small cell lung cancer patients |
| Q37584395 | Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives |
| Q57176317 | Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine |
| Q64956243 | Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and Abcb1/Abcg2-Deficient Mice. |
| Q89861115 | Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers |
| Q52318443 | Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment |
| Q91974558 | Brain Metastasis Mimicking Brain Abscess in ALK-Positive Non-Small-Cell Lung Cancer |
| Q39456912 | Brain Metastasis: Clinical Implications of Branched Evolution |
| Q58762991 | Brain Radiation Necrosis: Current Management With a Focus on Non-small Cell Lung Cancer Patients |
| Q58738654 | Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms |
| Q90428344 | Brain metastases in EGFR-positive non-small cell lung cancer: the way to the sanctuary becomes less winding |
| Q92134610 | Brain metastases in oncogene-driven non-small cell lung cancer |
| Q41593193 | Brain metastases in patients with non-small cell lung cancer: the role of mutated-EGFRs with an exon 19 deletion or L858R point mutation in cancer cell dissemination |
| Q31010216 | Brain metastasis: clinical characteristics, pathological findings and molecular subtyping for therapeutic implications |
| Q96134093 | Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer |
| Q41879369 | Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer |
| Q64228330 | Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer |
| Q38816270 | Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance |
| Q92530282 | Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis |
| Q91645996 | Complete Remission of Multiple Brain Metastases in a Patient with EGFR-Mutated Non-Small-Cell Lung Cancer Treated with First-Line Osimertinib without Radiotherapy |
| Q58083388 | Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis: A single institution retrospective analysis |
| Q52682138 | Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer |
| Q26738381 | Crizotinib resistance: implications for therapeutic strategies |
| Q42369337 | Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive for ALK translocation |
| Q57152399 | Development of metastatic brain disease involves progression through lung metastases in mutated non-small cell lung cancer |
| Q92159112 | EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis |
| Q59128276 | Editorial: Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment |
| Q91725652 | Effect of bevacizumab on brain radiation necrosis in anaplastic lymphoma kinase-positive lung cancer |
| Q90568504 | Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies |
| Q50045235 | Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer |
| Q89408783 | Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier |
| Q89544565 | Emerging findings into molecular mechanism of brain metastasis |
| Q64089193 | Emerging therapies for non-small cell lung cancer |
| Q48013012 | Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead |
| Q91314779 | Epidermal Growth Factor Receptor Mutation Status Confers Survival Benefit in Patients with Non-Small-Cell Lung Cancer Undergoing Surgical Resection of Brain Metastases: A Retrospective Cohort Study |
| Q52591097 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer. |
| Q53684267 | Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer. |
| Q64248736 | From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC |
| Q42367836 | Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. |
| Q92684950 | How I treat ALK-positive non-small cell lung cancer |
| Q38829087 | Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. |
| Q89622173 | Improving outcomes for brain metastases in EGFR mutated NSCLC |
| Q36322851 | Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? |
| Q52719909 | Intracranial control and survival outcome of tyrosine kinase inhibitor (TKI) alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer. |
| Q132041974 | KRAS G12C Mutant Non–Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry |
| Q90524093 | Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study |
| Q42339666 | Long-lasting response to third-line crizotinib treatment in a patient with non-small cell lung cancer with brain metastases and poor performance status. |
| Q38653663 | Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches |
| Q50146512 | Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. |
| Q92134573 | Molecular targeted therapies in non-small cell lung cancer: where we are |
| Q47108604 | Moving more potent and less toxic options to the frontline in the management of advanced lung cancer |
| Q96305342 | Neurological Death is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer Diagnosed With Brain Metastases |
| Q26746230 | New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib |
| Q38809939 | Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer. |
| Q92179030 | Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies |
| Q38991958 | Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience |
| Q54116816 | Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience. |
| Q39337110 | Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy. |
| Q28071903 | Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice |
| Q64068323 | Pharmacokinetic Study and Tissue Distribution of Lorlatinib in Mouse Serum and Tissue Samples by Liquid Chromatography-Mass Spectrometry |
| Q50927730 | Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer |
| Q40386800 | Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers |
| Q90367217 | Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases |
| Q64096504 | Rapid effect of osimertinib re-challenge on brain metastases developing during salvage cytotoxic chemotherapy after osimertinib treatment failure: A case report |
| Q91706155 | Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study |
| Q49307383 | Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA. |
| Q58577411 | Risk factors for brain metastases in patients with non-small-cell lung cancer |
| Q91638768 | Risk of brain metastases in T1-3N0 NSCLC: a population-based analysis |
| Q98613555 | Role of imaging biomarkers in mutation-driven non-small cell lung cancer |
| Q93185180 | Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer |
| Q54942435 | Stereotactic Radiosurgery in the Management of Patients With Brain Metastases of Non-Small Cell Lung Cancer: Indications, Decision Tools and Future Directions. |
| Q54978262 | Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. |
| Q91845628 | TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer |
| Q98938392 | Tackling brain metastases from lung cancer during the COVID-19 pandemic |
| Q49956245 | Targeted therapy of brain metastases: latest evidence and clinical implications |
| Q64067749 | Targeting Molecular Pathways in Intracranial Metastatic Disease |
| Q37737536 | The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer |
| Q89454905 | The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib |
| Q57174546 | The Prevention of Brain Metastases in Non-Small Cell Lung Cancer by Prophylactic Cranial Irradiation |
| Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases |
| Q89497176 | The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era |
| Q54967334 | Treating ALK-positive non-small cell lung cancer. |
| Q39039088 | Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it. |
| Q90132769 | Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer |
| Q61810591 | Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update |
| Q50139910 | Tumor biomarker testing in non-small-cell lung cancer: A decade of change. |
| Q47756656 | Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases |
| Q46915997 | Understanding and targeting resistance mechanisms in NSCLC. |
| Q58609576 | Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases |
| Q36427381 | Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. |
| Q53413935 | miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers. |
Search more.